Spotlight On... Actelion slaps $160K-plus price tag on new PAH med Uptravi; Allergan, Perrigo launch first-in-class Mucinex rival; Teva, Lupin roll out copies of Janssen contraceptive; and more...

Actelion thinks it can reach blockbuster heights with new pulmonary arterial hypertension (PAH) treatment Uptravi, approved by the FDA last month and launched earlier this week. And a price tag between $160,000 and $170,000 will certainly help it get there. Don't expect payers to balk at the lofty list price, though, the Swiss biotech's COO, Otto Schwarz, told analysts on a Tuesday call. Uptravi will come cheaper than rivals--including United Therapeutics' ($UTHR) Tyvaso--meaning that payers are unlikely to put up a fight. More from FiercePharma

> Allergan ($AGN) and Perrigo ($PRGO) have launched a store-brand version of Reckitt Benckiser's Mucinex D extended-release tablets. Release

> Teva ($TEVA) and Lupin have each launched a generic version of Johnson & Johnson's ($JNJ) oral contraceptive Ortho Tri-Cyclen Lo. Release | Release

> Teva and Takeda will shift Blopress for hypertension, Takepron for peptic ulcers, and Basen for Type 2 diabetes into a new company as part of their generics joint venture in Japan. More

> Roche ($RHHBY) and the U.K. Department of Health have begun trialing the Swiss drugmaker's RoActemra, an arthritis treatment, to see if it can be repurposed as a therapy for pulmonary arterial hypertension (PAH). Report

And Finally... The Wu-Tang Clan's de facto leader, RZA, says he doesn't regret selling the only copy of his group's latest album to indicted drug company exec Martin Shkreli. More

Suggested Articles

Leaked details about an ad campaign to quell coronavirus fears before the election raise "every red flag I could dream of," an ex-HHS official said.

The FDA approved GlaxoSmithKline's Nucala to treat hypereosinophilic syndrome, making it the first biologic approved for that disease.

There’s an emerging trend within the SMA community to pair treatments up in the hope that they may provide even better outcomes, one analyst notes.